Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
full-spectrum cannabidiol sublingual solution
- Development stage
- Unknown
- Lead developer
- McLean Hospital
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
This is a specific full-spectrum, high-cannabidiol (CBD) sublingual solution developed by Dr. Staci Gruber and her team at McLean Hospital's Marijuana Investigations for Neuroscientific Discovery (MIND) program. The formulation contains 9.97 mg/mL of CBD and trace amounts of delta-9-tetrahydrocannabinol (0.23 mg/mL THC), designed to leverage the potential synergistic 'entourage effect' of whole-plant cannabinoids. It is being investigated as an anxiolytic treatment for moderate-to-severe anxiety. In clinical evaluations, the product is administered as a sublingual tincture at a target daily dose of approximately 30 mg of CBD. Phase 2 clinical trials (NCT02548559) have demonstrated significant improvements in anxiety symptoms, mood, sleep, and executive function, while maintaining a favorable safety profile with no serious adverse events.
- Other names
- Full-Spectrum CannabidiolSublingual CannabidiolMIND-CBDsublingual CBD solution
02
Targets
CNR1 (Cannabinoid receptor 1)FAAHTRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on full-spectrum cannabidiol sublingual solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on full-spectrum cannabidiol sublingual solution.